Advertisement

x

Mathews Journal of Cancer Science

2474-6797

Mathews Journal of Cancer Science Reviewer Guidelines

Peer Review Process

Mathews Open Access Journals follows double blind peer review process. In this we do not reveal author names, affiliations to the reviewer and vice versa. We adhere to the Committee on Publication Ethics (COPE), code of conduct, and best practice guidelines (http://publicationethics.org). We strive to ensure that the peer review is fair, unbiased and timely. Decisions to accept or reject a manuscript for publication in the journal are based on the manuscript’s importance, originality, clarity, and the study’s validity and its relevance to remit of the journal. The process also involves strictly no plagiarism or fabrication of the data and parallel submissions.

Responsibilities

Being a reviewer you are accountable to take the responsibility of maintaining confidentiality of ideas that have been presented in the papers assigned to review. Focus your evaluation on merits and demerits of the article; assess the correctness, accuracy, clarity, and innovation of the research. Never reveal the assigned paper's results or videos/images or any of the supplementary material to non-reviewers.

The reviewers are given ample time for the review and submission of comments to the editorial office. Reviewers’ evaluations play a major role in our decision as to whether to accept a manuscript for publication.

Ethical Issues

  • The reviewer should be honest, transparent. Should not be biased in the decision, and exact analysis of the research.

  • After receiving the paper for any further assistance or clarifications you need to contact only the editorial office and the confidentiality of the paper has to be maintained.

  • You must never ask anyone to review a portion of paper without editor's permission and also must never contact the author of the paper directly.

  • Final decision in accepting/ rejecting of the manuscript is solely decided by Chief-Editor of the journal.

  • The reviewer can also inform the editor regarding suspected duplicate publication, plagiarism, or any ethical concerns about the use of animals or humans in the research that has be done by author.

Recently Published Articles
Research Article

Interactive Treatment Planning in High Dose-Rate Brachytherapy for Gynecological Cancer

Published : 03rd June 2022
Authors : Huan Liu1, Chenyang Shen2, Peter Klages2, Kevin Albuquerque2, Chang M Ma1*, Xun Jia2*
Citation : Chang-Ming Ma, Xun Jia, et al. (2022). Interactive Treatment Planning in High Dose-Rate Brachytherapy for Gynecological Cancer. Mathews J Cancer Sci. 7(2):31.

Case Report

Is Anaplastic Oligodendroglioma Prone to Extracranial Metastasis? A Case Report and Review of Literature

Published : 30th January 2022
Authors : Yanjun Zhang*#, Canliang Yuan*, Dequan Yu
Citation : Zhang Y, et al. (2022). Is Anaplastic Oligodendroglioma Prone to Extracranial Metastasis? A Case Report and Review of Literature. Mathews J Cancer Sci. 7(1):30.

Editorial note

On the Definition of Sievert and Its SI Unit

Published : 30th December 2021
Author : C-M Charlie Ma
Citation : Ma C-M. (2021). On the Definition of Sievert and Its SI Unit. Mathews J Cancer Sci. 6(1):29.

Research Article

A Clinical Study on Pulsed Low Dose Rate Radiation Therapy for Recurrent Cancers

Published : 21st December 2021
Authors : X Tong*, FS Luo, GR Yang, DP Wang, X Song, Y Chen, S Wu, N Zhang, QQ Xu, T Zhang, and J Li
Citation : Tong X. (2021). A Clinical Study on Pulsed Low Dose Rate Radiation Therapy for Recurrent Cancers. Mathews J Cancer Sci. 6(1):28.

Review Article

Clinical Applications of Pulsed Low Dose-Rate Radiation Therapy

Published : 21st May 2021
Author : Lili Chen
Citation : Chen L. (2021). Clinical Applications of Pulsed LowDose-Rate Radiation Therapy. Mathews J Cancer Sci. (6)1:27.

Research Article

The Role of Temozolomide-Irinotecan in Doxorubicin- Resistant Cell Lines of Recurrent Ewing’s Sarcoma, in A Patient Derived Orthotopic Xenograft (PDOX) with EWS-ERG Fusion and CDKN2A Loss: What Impact the Combination has in Real Life Practice?

Published : 08th October 2020
Authors : Maher Salamoon¹, Mehdi Balti², Bertrand Farnault³, Maher Saifo4, Ali Mahmoud5, Ahmad Khatib6, Manal Daghlawi7, Taisir Husein8, Mazen Kenj9, and Khaled Ghanem10
Citation : Salamoon M. (2020). The Role of Temozolomide-Irinotecan in Doxorubicin-Resistant Cell Lines of Recurrent Ewing’s Sarcoma, in A Patient Derived Orthotopic Xenograft (PDOX) with EWS-ERG Fusion and CDKN2A Loss: What Impact the Combination has in Real Life Practice?. Mathews J Cancer Sci. (5)1: 21.

Indexed
Root Indexing
J Gate
Scientific Indexing Services
Scilit
WolrdCat
Directory of Research Journals Indexing
Genamics JournalSeek
International Scientific Indexing
International Committee of Medical Journal Editors
CiteFactor
Subscribe

Subscribe to our RSS feed, be in touch with our articles, news, videos, reebies.

Antispam Code Generate new code

Creative Commons License

© 2015 Mathews Open Access Journals. All Rights Reserved.

Open Access by Mathews Open Access Journals is licensed under a
Creative Commons Attribution 4.0 International License.
Based On a Work at Mathewsopenaccess.com